#bpmc

  1. Assessing Blueprint Medicines: Insights From 16 Financial Analysts

    By Benzinga Insights In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ: BPMC ), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in
  2. 10 Health Care Stocks Whale Activity In Today's Session

    By Benzinga Insights This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market es
  3. Unveiling 18 Analyst Insights On Blueprint Medicines

    By Benzinga Insights Ratings for Blueprint Medicines (NASDAQ: BPMC ) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments ove
  4. C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

    By Avi Kapoor U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc . (NASDAQ: CHRW ) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results . C.H. Robi
  5. The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts

    By Benzinga Insights Blueprint Medicines (NASDAQ: BPMC ) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past